tiprankstipranks
Astellas Pharma Inc (ALPMF)
OTHER OTC:ALPMF

Astellas Pharma (ALPMF) Stock Price & Analysis

35 Followers

ALPMF Stock Chart & Stats

Day’s Range$9.52 - $9.52
52-Week Range― - ―
Previous Close$9.84
Volume253.00
Average Volume (3M)N/A
Market Cap
$17.35B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Jul 30, 2024
EPS EstimateN/A
Dividend Yield5.02%
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

0.00%0.00%<0.01%100.00%
0.00%
Insiders
0.00%
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors

ALPMF FAQ

What was Astellas Pharma Inc’s price range in the past 12 months?
Currently, no data Available
What is Astellas Pharma Inc’s market cap?
Currently, no data Available
When is Astellas Pharma Inc’s upcoming earnings report date?
Astellas Pharma Inc’s upcoming earnings report date is Jul 30, 2024 which is in 94 days.
    How were Astellas Pharma Inc’s earnings last quarter?
    Astellas Pharma Inc released its earnings results on Apr 25, 2024. The company reported -$0.125 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.125.
      Is Astellas Pharma Inc overvalued?
      According to Wall Street analysts Astellas Pharma Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Astellas Pharma Inc pay dividends?
        Astellas Pharma Inc pays a Semiannually dividend of $0.17 which represents an annual dividend yield of 5.02%. See more information on Astellas Pharma Inc dividends here
          What is Astellas Pharma Inc’s EPS estimate?
          Astellas Pharma Inc’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Astellas Pharma Inc have?
          Currently, no data Available
          What happened to Astellas Pharma Inc’s price movement after its last earnings report?
          Astellas Pharma Inc reported an EPS of -$0.125 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.237%.
            Which hedge fund is a major shareholder of Astellas Pharma Inc?
            Currently, no hedge funds are holding shares in ALPMF
            ---

            Astellas Pharma Stock Smart Score

            N/A
            Not Ranked
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Technicals

            SMA
            Negative
            20 days / 200 days
            Momentum
            -36.18%
            12-Months-Change

            Fundamentals

            Return on Equity
            0.96%
            Trailing 12-Months
            Asset Growth
            27.78%
            Trailing 12-Months

            Company Description

            Astellas Pharma Inc

            Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
            ---

            ALPMF Company Deck

            ---

            ALPMF Earnings Call

            Q4 2024
            0:00 / 0:00
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Takeda Pharmaceutical Company
            Pfizer
            Novartis
            Sanofi

            Best Analysts Covering ALPMF

            1 Year
            Unknown AnalystJefferies
            Not Ranked
            1 Year Success Rate
            0/0 ratings generated profit
            0%
            1 Year Average Return
            0.00%
            upgraded a buy rating 6 months ago
            Copying Unknown Analyst's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis